Andrew MBA - Monopar Therapeutics Chief Officer
| MNPR Stock | USD 19.40 0.70 3.48% |
Insider
Andrew MBA is Chief Officer of Monopar Therapeutics
| Age | 52 |
| Address | 1000 Skokie Boulevard, Wilmette, IL, United States, 60091 |
| Phone | 847 388 0349 |
| Web | https://www.monopartx.com |
Monopar Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5345) % which means that it has lost $0.5345 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0231) %, meaning that it created substantial loss on money invested by shareholders. Monopar Therapeutics' management efficiency ratios could be used to measure how well Monopar Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/25/2024, Return On Tangible Assets is likely to drop to -1.2. In addition to that, Return On Capital Employed is likely to drop to -1.66. At this time, Monopar Therapeutics' Total Assets are relatively stable compared to the past year. As of 11/25/2024, Total Current Assets is likely to grow to about 11.2 M, while Non Current Assets Total are likely to drop slightly above 12 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| James JD | Eliem Therapeutics | 58 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| Hing Wong | HCW Biologics | 70 | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| MD BA | Lumos Pharma | 69 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| Lisa Miller | Lumos Pharma | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
| Carl Langren | Lumos Pharma | 69 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| Jeff York | Seres Therapeutics | N/A | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| David MBA | Seres Therapeutics | 63 | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Bradley JD | Lumos Pharma | 45 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Lori CPA | Lumos Pharma | 40 | |
Management Performance
| Return On Equity | -1.02 | ||||
| Return On Asset | -0.53 |
Monopar Therapeutics Leadership Team
Elected by the shareholders, the Monopar Therapeutics' board of directors comprises two types of representatives: Monopar Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Monopar. The board's role is to monitor Monopar Therapeutics' management team and ensure that shareholders' interests are well served. Monopar Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Monopar Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Starr, CoFounder Board | ||
| Andrew MBA, Chief Officer | ||
| Kim CPA, Secretary, CFO | ||
| MBA MD, CEO, CoFounder | ||
| Karthik CFA, Principal CFO |
Monopar Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Monopar Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.02 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 98.82 M | ||||
| Shares Outstanding | 5.28 M | ||||
| Shares Owned By Insiders | 42.94 % | ||||
| Shares Owned By Institutions | 24.47 % | ||||
| Number Of Shares Shorted | 72.01 K | ||||
| Price To Earning | (35.82) X | ||||
| Price To Book | 21.45 X | ||||
| EBITDA | 429.04 K |
Pair Trading with Monopar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Monopar Stock
| 0.86 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.82 | AGL | agilon health Buyout Trend | PairCorr |
| 0.81 | NKTX | Nkarta Inc | PairCorr |
| 0.79 | MTEM | Molecular Templates | PairCorr |
| 0.78 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.
The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.